Sept. 27, 2021 – In the midst of public scrutiny regarding clinical trial transparency, the Food and Drug Administration (FDA) and the United Kingdom’s Health Research Agency (HRA) recently took actions that may indicate their increased willingness to more closely monitor clinical investigators who do not report trial results in a timely manner. “Pharma, researchers, […]
Read more
June 8, 2018 – Sen. Claire McCaskill (D-Mo.), who announced a bill in March that would amend the tax code to “deny the deduction for advertising and promotional expenses for prescription drugs,” continues to look for ways to restrict prescription drug company activities, now introducing a bill that would significantly expand reporting under the Sunshine […]
Read more
Feb. 5, 2018 – A bill to increase price transparency in Oregon, scheduled to be introduced Feb. 5, would require prescription drug manufacturers not only to report drug prices to the state annually, but also would require them to report costs associated with developing and marketing their drugs. If passed, Oregon House Bill 4005 would […]
Read more July 5, 2017 – While deregulation takes hold in the Trump administration in Washington, the states are predictably working to fill the void. For medical transparency and “sunshine,” California, Maine and Nevada are currently very active. All three states have taken legislative action in recent months to restrict the ability of pharmaceutical companies to furnish […]
Read more
Coalition Commentary by Executive Director John Kamp April 17, 2017 — Agencies, media and clients all need to watch closely as this Congress looks to regulate medical manufacturers’ real or perceived excess profits, or at least bring down the cost of medical products for citizens. So far, the political heat on medicine companies has not […]
Read moreApril 7, 2014 – Although the Physician Payment Sunshine Act preempts state laws that require reporting of similar information required under the Act, several states continue to call for the reporting of additional information that relates to gifts, payments or other transfers of value, according to an article posted last week by Policy and Medicine. […]
Read moreOct. 11, 2011 – The FDA is seeking to provide more complete compliance and enforcement data to the public and regulated industry, according to a document issued last week by the agency’s Transparency Task Force. The document, “Draft Proposals for Public Comment to Increase Transparency by Promoting Greater Access to the Agency’s Compliance and Enforcement […]
Read more